Lymphoma
Lymphoma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
60
Clinical Trials
Lymphoma
NA
Active
nct/study# NCT04981795 / MOR208C414
Prospective Multicenter Observational Study Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Starting Second- Or Third-Line Therapy And Not Receiving Autologous Stem Cell Transplant (REAL-MIND)
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2020-0081
Outcomes Of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Patients: Real World Experience In Lymphoma Patients
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2021-0345
Outcomes And Prognostic Factors Of Patients Diagnosed With High-Grade B-Cell Lymphoma, Not Otherwise Specified: A Multi-Institutional Retrospective Study
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT03331198 / 017004
An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004)
Learn More
Lymphoma
Phase III
Accepting Patients
nct/study# NCT03575351 / JCAR017-BCM-003
A Global Randomized Multicenter Phase 3 Trial Of JCAR017 Compared To Standard Of Care In Adult Subjects With High-Risk, Second-Line, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM).
Learn More
Lymphoma
N/A
Active
nct/study# NCT04982471 / NDS-DLBCL-003
Connect® Lymphoma Disease Registry: A Us-Based Prospective Observational Cohort Study
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.